Detalles de la búsqueda
1.
Utility of 68 Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia.
Intern Med J
; 51(10): 1657-1664, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33314504
2.
Synthesis of [18F]F-γ-T-3, a Redox-Silent γ-Tocotrienol (γ-T-3) Vitamin E Analogue for Image-Based In Vivo Studies of Vitamin E Biodistribution and Dynamics.
Molecules
; 25(23)2020 Dec 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33287202
3.
Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study.
Eur J Nucl Med Mol Imaging
; 46(8): 1596-1604, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31044265
4.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Lancet Oncol
; 19(6): 825-833, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29752180
5.
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 44(3): 476-489, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27678267
6.
Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
J Pediatr Hematol Oncol
; 38(2): 87-96, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26296147
7.
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.
Eur J Nucl Med Mol Imaging
; 42(2): 176-85, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25209134
8.
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Eur J Nucl Med Mol Imaging
; 42(1): 25-32, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25125202
9.
High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT.
Eur J Nucl Med Mol Imaging
; 41(2): 343-9, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24196920
10.
Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.
Eur J Nucl Med Mol Imaging
; 40(12): 1853-60, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23864305
11.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
J Nucl Med
; 64(1): 69-74, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35738906
12.
Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
J Nucl Med
; 64(2): 221-226, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36008120
13.
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Ther Adv Med Oncol
; 15: 17588359231156392, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36872949
14.
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.
J Nucl Med
; 63(4): 560-566, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326127
15.
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Eur Urol Oncol
; 4(6): 963-970, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758400
16.
Segmental hyperperfusion in lobar pneumonia visualized with respiratory-gated four-dimensional pulmonary perfusion positron emission tomography-computed tomography.
Am J Respir Crit Care Med
; 189(1): 104-5, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24381992
17.
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.
Sci Rep
; 10(1): 10196, 2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576907
18.
Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.
Front Pharmacol
; 11: 1291, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32973520
19.
Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer.
BMJ Open
; 10(12): e042465, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33303468
20.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med
; 61(6): 857-865, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732676